Skip to main content

Cav2.2 Antibody

Novus Biologicals, part of Bio-Techne | Catalog # NBP3-30952

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP3-30952-100ug
NBP3-30952-25ug

Key Product Details

Species Reactivity

Human

Applications

Western Blot

Label

Unconjugated

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

Synthetic peptide derived from the rat Cav2.2 conjugated to KLH

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for Cav2.2 Antibody

Application
Recommended Usage

Western Blot

: 1:400
Application Notes
.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Formulation

Phosphate buffered saline

Preservative

0.08% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C. Avoid freeze-thaw cycles.

Background: Cav2.2

Voltage-sensitive calcium channels (VSCCs) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death.

Long Name

Voltage-dependent N-type calcium channel subunit alpha-1B

Alternate Names

BIII, CACH5, CACNA1B, CACNL1A5

Gene Symbol

CACNA1B

Additional Cav2.2 Products

Product Documents for Cav2.2 Antibody

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Cav2.2 Antibody

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...